MEDIROM enters rehabilitation sector with new subsidiary

Published 07/10/2024, 21:06
MEDIROM enters rehabilitation sector with new subsidiary

TOKYO - MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), a provider of holistic health services, has announced its entry into the rehabilitation industry through the establishment of a new subsidiary, MEDIROM Rehab Solutions Inc. The subsidiary has acquired all rehabilitation centers previously owned by Y's, Inc., which includes ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan.

Cerebral infarction rehabilitation is a specialized program aimed at aiding recovery for stroke victims. The acquired centers offer a range of services including physical, occupational, speech, and cognitive therapies, as well as emotional support for patients who have suffered strokes due to blood vessel blockages in the brain.

Kouji Eguchi, CEO of Medirom, expressed optimism about the expansion, noting the company's intention to leverage its existing wellness clinic expertise and health-tech capabilities to enhance the rehabilitation services provided by the newly formed subsidiary.

MEDIROM Rehab Solutions Inc., led by CEO Yasuhiro Ito, was established on June 10, 2024, and operates from Tokyo. The company's focus is on delivering cerebral infarction rehabilitation services, which are not covered by insurance, and providing contracted rehabilitation services.

MEDIROM Healthcare Technologies, founded in 2000, operates across three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The company's foray into the rehabilitation space marks a significant step in diversifying its service offerings.

This expansion is based on a press release statement and represents a strategic move by MEDIROM to integrate its healthcare technology with on-ground services to address the needs of stroke rehabilitation patients in Japan.

In other recent news, MEDIROM Healthcare Technologies Inc. has announced a significant acquisition. The company will acquire 70% of Japan Gene Medicine Corporation, a firm specializing in prenatal genetic testing and analysis. This agreement, set to be effective on June 30, 2024, also includes an option for MEDIROM to secure the remaining 30% of shares via an Additional Transfer Memorandum of Understanding.

This move, part of MEDIROM's strategy to expand its HealthTech solutions portfolio, is expected to create synergies with its existing wellness salon business. The acquisition is based on an enterprise value of six times Adjusted EBITDA, with the total price of the 70% share acquisition being 2 billion yen. The transaction will be financed through the company's funds and borrowings.

A special purpose company will be established to facilitate the transaction, which is subject to various conditions. The transaction's closing date will be determined once all conditions are met. The Additional Transfer Memorandum of Understanding allows for the potential purchase of the remaining shares by June 30, 2027.

InvestingPro Insights

MEDIROM Healthcare Technologies Inc.'s recent expansion into the rehabilitation industry comes at a critical time for the company. According to InvestingPro data, MEDIROM's revenue growth has been negative, with a -1.81% decline in the last twelve months as of Q4 2023. This move into the rehabilitation sector could be seen as a strategic effort to diversify and potentially boost revenue streams.

However, investors should be cautious. InvestingPro Tips highlight that MEDIROM "operates with a significant debt burden" and "may have trouble making interest payments on debt." These factors could pose challenges as the company invests in its new subsidiary and acquired rehabilitation centers.

The company's stock performance has been concerning, with InvestingPro data showing a -52.78% total return over the past year. This aligns with the InvestingPro Tip indicating that the "stock has taken a big hit over the last six months." The expansion into rehabilitation services could be viewed as an attempt to reverse this trend and create new growth opportunities.

Despite these challenges, it's worth noting that MEDIROM has been "profitable over the last twelve months," according to InvestingPro Tips. This profitability, combined with the strategic expansion, may provide some optimism for the company's future prospects.

For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for MEDIROM Healthcare Technologies Inc., providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.